|Videos|May 5, 2023
Audience Q&A: Best Practices in Managing HER2-Amplified CRC
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
5